Hill, B., Switchenko, J., Martin, P., Churnetski, M., Sawalha, Y., Goyal, S., Shanmugasundaram, K., Calzada, O., Kolla, B., Bachanova, V., Gerson, J., Barta, S., Maldonado, E., Gordon, M., Danilov, A., Grover, N., Mathews, S., Burkart, M., Karmali, R., Ghosh, N., Park, S., Epperla, N., Bond, D., Badar, T., Blum, K., Guo, J., Hamadani, M., Fenske, T., Malecek, M., Maddocks, K., Flowers, C., Kahl, B., & Cohen, J. (n.d.). mAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). Hematological oncology, 37, 405–407. http://access.bl.uk/ark:/81055/vdc_100086208575.0x000037